SynthesisNaunyn-Schmiedeberg's archives of pharmacology2025
Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
Synthesis in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data.Therapeutic advances in respiratory diseasePooled it
- Lifesaving Compassionate-Use of Sotatercept in a 12-Year-old With Idiopathic Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- Paradigm shift: from pulmonary vasodilation to cardiopulmonary dual-track therapy-a comprehensive review of pathophysiology and advances in pulmonary hypertension-associated right heart failure.Respiratory research · 2026Review
- Sotatercept in pulmonary arterial hypertension: revolution, risk and the road ahead.The European respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling and high mortality. Sotatercept, a novel activin signaling inhibitor, targets the underlying vascular pathology and offers therapeutic potential beyond current vasodilator-based therapies. A comprehensive search of PubMed, Web of Science, SCOPUS, and the Cochrane Library was performed up to April 2, 2025. Only randomized controlled trials (RCTs) comparing sotatercept to placebo in adults with PAH were included. Outcomes were pooled using random-effects models and reported as mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI). Trial sequential analysis (TSA) was conducted for statistically significant outcomes. PROSPERO ID: CRD420251031657. Three RCTs and 601 patients were included. Sotatercept significantly improved 6-min walk distance (MD = 40.17 m; 95% CI 15.14-65.19), decreased NT-proBNP (MD = - 1149.48 pg/mL; 95% CI - 1890.21 to - 458.73), improved WHO functional class (RR = 2.04; 95% CI 1.53-2.70), and decreased pulmonary vascular resistance (MD = - 214.58; 95% CI - 217.54 to - 211.62). Also, sotatercept decreased all-cause mortality (RR = 0.46; 95% CI 0.22-0.98) and right ventricular failure (RR = 0.26; 95% CI 0.09-0.75); however, it increased thrombocytopenia risk (RR = 2.01; 95% CI 1.01-3.98). Sotatercept significantly improves exercise capacity, cardiac biomarkers, functional status, and pulmonary hemodynamics in patients with PAH while reducing all-cause mortality and right ventricular failure. Despite a mild increase in the risk of thrombocytopenia, it remains a promising disease-modifying therapy.
Indexed as
Identifiers
40668414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.